Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neulapeg prophylaxis in pancreatic cancer treated with mFOLFIRINOX
NCT06353581Phase 2Active, not recruiting
- Sponsor
- Yonsei University
- Start
- Feb 2022
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegteograstim in neutropenia, sponsored by Yonsei University. Started Feb 2022; status: active, not recruiting.
02
Drugs
pegteograstim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT06353581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06353581.